Full Name
ROSS ANDREW SOO
Variants
Ross, S.
Soo, R.
Soo, R.-A.
Soo, R.A.
Soo, Ross
 
 
 
Email
csiras@nus.edu.sg
 

Publications

Results 1-20 of 65 (Search time: 0.034 seconds).

Issue DateTitleAuthor(s)
1Apr-2012A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNg, K.P.; Hillmer, A.M.; Chuah, C.T.H.; Juan, W.C.; Ko, T.K. ; Teo, A.S.M.; Ariyaratne, P.N.; Takahashi, N.; Sawada, K.; Fei, Y.; Soh, S.; Lee, W.H.; Huang, J.W.J.; Allen Jr., J.C.; Woo, X.Y.; Nagarajan, N.; Kumar, V.; Thalamuthu, A.; Poh, W.T.; Ang, A.L.; Mya, H.T.; How, G.F.; Yang, L.Y.; Koh, L.P.; Chowbay, B.; Chang, C.-T.; Nadarajan, V.S.; Chng, W.J.; Than, H.; Lim, L.C.; Goh, Y.T.; Zhang, S.; Poh, D.; Tan, P. ; Seet, J.-E.; Ang, M.-K.; Chau, N.-M.; Ng, Q.-S.; Tan, D.S.W.; Soda, M.; Isobe, K.; Nöthen, M.M.; Wong, T.Y. ; Shahab, A.; Ruan, X.; Cacheux-Rataboul, V.; Sung, W.-K.; Tan, E.H.; Yatabe, Y.; Mano, H.; Soo, R.A. ; Chin, T.M. ; Lim, W.-T.; Ruan, Y. ; Ong, S.T.
225-Mar-2020A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaKong, Li Ren ; Salleh, Nur Afiqah Binte Mohamed ; Ong, Richard Weijie; Tan, Tuan Zea ; Syn, Nicholas L; Goh, Robby Miguel; Fhu, Chee Wei ; Tan, Daniel SW ; Iyer, N Gopalakrishna ; Kannan, Srinivasaraghavan; Verma, Chandra S ; Lim, Yaw Chyn ; Soo, Ross ; Ho, Jingshan ; Huang, Yiqing; Lim, Joline SJ ; Yan, Benedict Junrong; Nga, Min En ; Lim, Seng Gee ; Koeffler, H Phillip ; Lee, Soo Chin ; Kappei, Dennis ; Hung, Huynh The ; Goh, Boon Cher 
3Nov-2011A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapyKoh, T.S.; Thng, C.H.; Hartono, S.; Tai, B.C. ; Rumpel, H.; Ong, A.B.; Sukri, N.; Soo, R.A. ; Wong, C.I.; Low, A.S.C.; Humerickhouse, R.A.; Goh, B.C.
4Apr-2008A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsMa, B.; Goh, B.C.; Tan, E.H.; Lam, K.C.; Soo, R. ; Leong, S.S.; Wang, L.Z. ; Mo, F.; Chan, A.T.C.; Zee, B.; Mok, T.
5Jul-2006A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancerSoo, R.A. ; Wang, L.Z. ; Tham, L.S.; Yong, W.P. ; Boyer, M.; Lim, H.L.; Lee, H.S.; Millward, M.; Liang, S.; Beale, P.; Lee, S.C. ; Goh, B.C.
6Jul-2008A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancersYong, W.-P. ; Wang, L.-Z. ; Tham, L.-S.; Wong, C.-I.; Lee, S.-C. ; Soo, R. ; Sukri, N.; Lee, H.-S.; Goh, B.-C.
72017A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancerSoh, S.X; Siddiqui, F.J ; Allen, J.C ; Kim, G.W; Lee, J.C; Yatabe, Y; Soda, M; Mano, H; Soo, R.A ; Chin, T.-M ; Ebi, H; Yano, S; Matsuo, K; Niu, X; Lu, S; Isobe, K; Lee, J.-H; Yang, J.C; Zhao, M; Zhou, C; Lee, J.-K; Lee, S.-H; Lee, J.Y; Ahn, M.-J; Tan, T.J; Tan, D.S ; Tan, E.-H; Ong, S.T ; Lim, W.-T 
82017Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysisKoh K.X.; Tan G.H.; Low S.H.H. ; Omar M.F.M. ; Han M.J.; Iacopetta B.; Soo R. ; Beloueche-Babari M.; Bhattacharya B. ; Soong R. 
9Oct-2012Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutationKim, S.M.; Kwon, O.-J.; Hong, Y.K.; Kim, J.H.; Solca, F.; Ha, S.-J.; Soo, R.A. ; Christensen, J.G.; Lee, J.H.; Cho, B.C.
102016Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its developmentWang, L ; Khoa Phan, D.D; Zhang, J; Ong, P.-S ; Thuya, W.L ; Soo, R.A ; Wong, A.L.-A ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
11Oct-2013Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequenciesLoh, M. ; Chua, D.; Yao, Y.; Soo, R.A. ; Garrett, K.; Zeps, N.; Platell, C.; Minamoto, T.; Kawakami, K.; Iacopetta, B.; Soong, R. 
12May-2009Clinical pharmacology and pharmacogenetics of gemcitabineWong, A.; Soo, R.A. ; Yong, W.-P. ; Innocenti, F.
132017Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1Wang, L ; Chan, C.E.L; Wong, A.L.-A ; Wong, F.C; Lim, S.W ; Chinnathambi, A; Alharbi, S.A; Lee, L.S.-U ; Soo, R ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
14Apr-2012Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapySoo, R.A. ; Kawaguchi, T.; Loh, M. ; Ou, S.-H.I.; Shieh, M.P.; Cho, B.-C.; Mok, T.S.; Soong, R. 
1513-Aug-2019Different treatment efficacies and side effects of cytotoxicchemotherapyWang Lingzhi ; Chong Qing Yun ; Goh Boon Cher ; Soo Ross ; Li Low-Jia
162018Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapyLimviphuvadh, V; Tan, C.S; Konishi, F; Jenjaroenpun, P; Xiang, J.S; Kremenska, Y; Mu, Y.S; Syn, N; Lee, S.C; Soo, R.A ; Eisenhaber, F ; Maurer-Stroh, S ; Yong, W.P 
171-Feb-2012Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangementKim, H.R.; Shim, H.S.; Chung, J.-H.; Lee, Y.J.; Hong, Y.K.; Rha, S.Y.; Kim, S.H.; Ha, S.-J.; Kim, S.K.; Chung, K.Y.; Soo, R. ; Kim, J.H.; Cho, B.C.
18Dec-2008Does saturable formation of gemcitabine triphosphate occur in patients?Tham, L.-S.; Wang, L.-Z. ; Soo, R.A. ; Lee, H.-S.; Lee, S.-C. ; Goh, B.-C.; Holford, N.H.G.
192016EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interactionKumarakulasinghe, N.B; Syn, N; Soon, Y.Y; Asmat, A; Zheng, H; Loy, E.Y; Pang, B ; Soo, R.A 
20Jun-2011Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trialsSoo, R.A. ; Loh, M. ; Mok, T.S.; Ou, S.-H.I.; Cho, B.-C.; Yeo, W.-L. ; Tenen, D.G.; Soong, R.